Source:http://linkedlifedata.com/resource/pubmed/id/17313557
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
2
|
| pubmed:dateCreated |
2007-2-22
|
| pubmed:abstractText |
High-dose chemotherapy (HD-CT) with autologous stem cell transplantation is considered to be the treatment of choice for relapsed high-grade non-Hodgkin's lymphoma (NHL) and Hodgkin's lymphoma (HL) patients, but the optimal treatment has not yet been defined. We evaluated a salvage treatment regimen consisting of conventional cycles with ifosfamide, etoposide, cytarabine, and dexamethasone (IVAD) followed by two cycles of HD-CT consisting of cyclophosphamide, melphalan, and etoposide (CMV) with autologous stem cell support in patients with relapsed or refractory NHL (n = 59) and HL (n = 16). Response to IVAD was complete remission (CR) in 16 patients (21%), partial remission (PR) in 39 patients (52%), stable disease (SD) in 18 patients (24%), and progressive disease (PD) in two patients (2.7%). Of 70 patients treated with HD-CT, 41 patients (59%) showed a CR, 20 patients a PR (29%), eight patients a SD (11%), and one patient a PD (1.4%). The 5-yr overall survival for the entire group of patients was 29%, and for patients with NHL and HL 25%, and 38%, respectively. The respective event-free survival probabilities at 5 yr were 22%, 16%, and 31%. Seven treatment-related deaths due to septicemia (three), cardiac arrhythmia (one), pneumonia (one), pneumonitis (one), and toxic epidermal necrolysis (one) were observed. In multivariate analysis, an International Prognostic Index of > or = 2 and resistant disease to first-line chemotherapy were poor independent prognostic factors for the subgroup of patients with NHL. In conclusion, these results indicate that IVAD/CMV is feasible as a salvage therapy for lymphoma patients. This treatment is currently evaluated with the addition of rituximab.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Cyclophosphamide,
http://linkedlifedata.com/resource/pubmed/chemical/Cytarabine,
http://linkedlifedata.com/resource/pubmed/chemical/Dexamethasone,
http://linkedlifedata.com/resource/pubmed/chemical/Etoposide,
http://linkedlifedata.com/resource/pubmed/chemical/Ifosfamide,
http://linkedlifedata.com/resource/pubmed/chemical/Melphalan
|
| pubmed:status |
MEDLINE
|
| pubmed:month |
Feb
|
| pubmed:issn |
0902-4441
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
78
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
93-101
|
| pubmed:dateRevised |
2010-11-18
|
| pubmed:meshHeading |
pubmed-meshheading:17313557-Adult,
pubmed-meshheading:17313557-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:17313557-Bone Marrow Diseases,
pubmed-meshheading:17313557-Combined Modality Therapy,
pubmed-meshheading:17313557-Cyclophosphamide,
pubmed-meshheading:17313557-Cytarabine,
pubmed-meshheading:17313557-Dexamethasone,
pubmed-meshheading:17313557-Drug Resistance, Neoplasm,
pubmed-meshheading:17313557-Etoposide,
pubmed-meshheading:17313557-Female,
pubmed-meshheading:17313557-Follow-Up Studies,
pubmed-meshheading:17313557-Gastrointestinal Diseases,
pubmed-meshheading:17313557-Hodgkin Disease,
pubmed-meshheading:17313557-Humans,
pubmed-meshheading:17313557-Ifosfamide,
pubmed-meshheading:17313557-Kaplan-Meier Estimate,
pubmed-meshheading:17313557-Lymphoma,
pubmed-meshheading:17313557-Lymphoma, Non-Hodgkin,
pubmed-meshheading:17313557-Male,
pubmed-meshheading:17313557-Melphalan,
pubmed-meshheading:17313557-Middle Aged,
pubmed-meshheading:17313557-Neutropenia,
pubmed-meshheading:17313557-Peripheral Blood Stem Cell Transplantation,
pubmed-meshheading:17313557-Recurrence,
pubmed-meshheading:17313557-Remission Induction,
pubmed-meshheading:17313557-Salvage Therapy,
pubmed-meshheading:17313557-Sepsis,
pubmed-meshheading:17313557-Survival Rate,
pubmed-meshheading:17313557-Transplantation, Autologous,
pubmed-meshheading:17313557-Treatment Outcome
|
| pubmed:year |
2007
|
| pubmed:articleTitle |
Ifosfamide, etoposide, cytarabine, and dexamethasone as salvage treatment followed by high-dose cyclophosphamide, melphalan, and etoposide with autologous peripheral blood stem cell transplantation for relapsed or refractory lymphomas.
|
| pubmed:affiliation |
Department of Internal Medicine (Cancer Research), West German Cancer Center, University of Duisburg-Essen Medical School, Essen, Germany.
|
| pubmed:publicationType |
Journal Article,
Clinical Trial, Phase II
|